Tilray stock prints bullish candle ahead of Trump cannabis executive order

Core Insights - Tilray's stock price surged nearly 30% on Tuesday, reaching a high of $14.40, in anticipation of Donald Trump's executive order to reschedule cannabis into a lower drug classification [1] Company Impact - The significant increase in Tilray's stock price reflects investor optimism regarding potential regulatory changes that could benefit the cannabis industry [1] Industry Implications - The rescheduling of cannabis could lead to broader market acceptance and increased investment in the cannabis sector, potentially transforming the landscape for cannabis-related companies [1]